This cluster is entirely director-level selling with no C-suite participation, totaling just 0.011% of market cap, well below any materiality threshold. The sales are likely liquidity-driven following derivative exercises. No actionable signal for traders; ignore this cluster.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 2 $9.44entry
- T+1 · 4mo ago −5.61%α −6.49% · $8.91
- T+5 · 4mo ago −12.92%α −14.29% · $8.22
- T+20 · 4mo ago −24.05%α −24.35% · $7.17
- T+60 · 7w ago −9.75%α −12.54% · $8.52
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two directors at ImmunityBio sold a combined ~$1.06M in open-market sales over a 7-day window, with the largest sale ($862K) occurring on June 29 at ~$9.01. The cluster is 100% selling by non-C-suite directors, with total value representing ~0.01% of the $9.6B market cap, well below the 0.1% materiality threshold. The sales are trivial relative to company size and carry no informational signal per the academic literature on director-level sales.
Key Financial Metrics
Key Facts
- Two directors sold a combined ~$1.06M in open-market sales over a 7-day window ending June 29, 2026
- Total sales represent ~0.011% of IBRX's $9.6B market cap, well below the 0.1% materiality threshold
- No C-suite executives (CEO, CFO, COO) participated in any trades, only directors
- Director Selecky Christobel's sales ($871K) were preceded by derivative exercises at $2.98 strike, suggesting tax/vesting-related liquidity rather than a bearish view
- Director Simon Barry J. sold $197K at $7.88, a trivial amount for a $9.6B company
Financial Impact
Total insider sales of ~$1.06M represent ~0.011% of IBRX's $9.6B market cap, trivial and routine
Risk Factors
- No C-suite participation in this cluster, director-level sales carry minimal informational content
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-IBRX-1782976386047 |
Track record
11 reports on IBRX
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +19.12% at T+60 after the Apr 9, 2026 report. 2 of 5 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $7.11 Now $5.98 −15.89% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $8.93 Now $5.98 −33.03% settles Feb 2
- Oct 14, 20264w ago 8-K Bullish 7/10 Entry $10.00 Now $5.98 −40.20% settles Jan 12
- Aug 4, 202614w ago 8-K Neutral 5/10 Entry $6.95 to $8.63 Now $5.98 −13.96% ▲ +24.17% +24.39% vs SPY
- Jul 6, 202619w ago Insider Cluster Neutral 2/10 Entry $8.76 to $9.44 Now $5.98 −31.74% ▲ +7.76% +5.77% vs SPY
- Jul 1, 202619w ago Insider Cluster Neutral 2/10 Viewing Entry $9.44 to $8.52 Now $5.98 −36.65% ▼ −9.75% −12.54% vs SPY
- May 18, 202626w ago 8-K Bullish 5/10 Entry $7.76 to $7.65 Now $5.98 −22.94% ▼ −1.42% −7.71% vs SPY
- Apr 9, 202631w ago 8-K Bullish 8/10 Entry $7.48 to $8.91 Now $5.98 −20.05% ▲ +19.12% +8.34% vs SPY
- Apr 6, 202632w ago 8-K Neutral 4/10 Entry $7.08 to $9.20 Now $5.98 −15.54% ▲ +29.94% +16.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers